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ABSTRACT
In head and neck squamous cell cancer (HNSCC), four intrinsic subtypes (or 
groups) have been identified, and each one possesses a unique biology that will require 
specific treatment strategies. We previously reported that mesenchymal (group 2) 
tumors exhibit reduced levels of Trop2 expression. In this study, we investigated the 
functional role of Trop2 in HNSCC and find that loss results in autocrine activation 
of the EGFR family member ErbB3 via neuregulin-1. Trop2 localizes to both the cell 
surface and cytosol of HNSCC cells and forms a complex with neuregulin-1, which 
is predominantly cytosolic. Inactivation of Trop2 increases the concentration of 
neuregulin-1 at the cell surface where it is cleaved to activate ErbB3. In primary 
HNSCC, detection of ErbB3 activation was limited to Trop2 negative tumors. An 
analysis of the Cancer Genome Atlas (TCGA) HNSCC dataset confirms enrichment 
for ErbB3 activity in mesenchymal tumors. Notably, Trop2 loss triggers sensitivity to 
anti-ErbB3 antibodies, which results in reduced proliferation and tumorigenic growth 
of Trop2 negative HNSCC cancer cells. These results uncover a molecular mechanism 
by which tumor cells control the amount of cell-surface neuregulin-1 available for 
cleavage and ErbB3 activation. Moreover, we demonstrate that Trop2 is a potential 
surrogate biomarker to identify tumors with ErbB3 activation and may therefore 
respond to anti-ErbB3 therapeutics. 
INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is a highly heterogeneous disease whose behavior is 
dictated by the site of origin within the head and neck as 
well as the underlying etiology [1]. Molecular profiling 
of these biologically heterogeneous tumors has revealed 
four distinct subtypes [2]. Recently this classification was 
validated by Walter, et al. and The Cancer Genome Atlas 
(TCGA) Project in two independent tumor dataset [3, 4], 
and the nomenclature has now been updated to reflect their 
biology: basal (Group 1), mesenchymal (Group 2), atypical 
(Group 3) and classical (Group 4) [3]. HNSCC subtypes 
have been found to possess unique biological features that 
are associated with very different outcomes. For example, 
basal tumors were reported to exhibit high EGFR pathway 
activity, while mesenchymal tumors, which comprise 
approximately twenty-five percent of HNSCC, exhibited 
low EGFR activity; the atypical subtype was enriched in 
human papillomavirus-related HNSCC; and the classical 
subtype was shown to be enriched for genes associated 
with exposure to cigarette smoke [2, 3]. Despite the recent Oncotarget 9282 www.impactjournals.com/oncotarget
validation of the HNSCC subtypes, much remains to be 
learned concerning their biology before knowledge of the 
subtypes will have an impact on clinical decision-making. 
This situation lies in stark contrast to the successful 
application of subtype information in other tumor types 
such as breast [5] and colon [6] cancer, where molecular 
subtyping guides the selection of targeted therapies as well 
as the rational development of experimental therapeutics.
We recently reported that expression of Trop2, a 
transmembrane protein that is emerging as a pleiotropic 
mediator of growth and survival signals, is significantly 
reduced or lost in mesenchymal HNSCC tumors [7]. 
Trop2 consists of a large extracellular domain, a single-
pass transmembrane domain, and a twenty-six amino acid 
tail. Oncogenic signaling can be initiated either by gain- 
or loss-of-function depending on cell type and context. 
Ectopic Trop2 expression was shown by our group as 
well as others to promote tumor growth in NIH3T3 [8] 
and pancreatic cancer [9] cells, respectively. Other studies 
indicate a pro-tumorigenic consequence for Trop2 loss. 
Using a skin carcinogenesis assay in a Trop2 knockout 
animal, we showed that Trop2 deletion contributes to 
squamous cell tumorigenesis [7]. More recently, it was 
reported that the Trop2 gene locus is methylated in a 
significant fraction of adenocarcinomas of the lung and 
that this loss contributes to aggressiveness in that disease 
[10].
The ErbB receptor family plays an important role 
in HNSCC. Basal subtype tumors are suggested to signal 
predominantly through epidermal growth factor receptor 
(EGFR) [2]. Other ErbB family members – ErbB2 
and ErbB3 – have also been reported to be commonly 
expressed  in  HNSCC,  but  their  significance  and 
relationship to subtype in HNSCC is less well established 
[11-13]. Although members of this superfamily share 
basic structural features, each one exhibits unique 
properties that contextualize their signaling, diversify 
the range of outputs, and determine patterns of response 
to therapeutic inhibition [14]. No ligand for ErbB2 has 
yet to be identified, but the gene is often amplified in 
breast and gastric cancer and is potently oncogenic in 
multiple experimental systems [15, 16]. ErbB3 (HER3) 
is notable as the only EGFR family member that is unable 
to homodimerize, and it also lacks strong intrinsic kinase 
activity [17]. As such, it requires dimerization with and 
transphosphorylation by its preferred partner, ErbB2, but 
it can also dimerize with ErbB4, or EGFR, upon which 
ErbB3 potently activates the PI3 kinase pathway [18]. 
The initiating signals that influence ErbB3 activation are 
diverse and include post-translational modifications such 
as translocation from intracellular stores [19]. Recently, 
ligand-independent mutational activation of ErbB3 
has been reported [20], but autocrine signaling via the 
neuregulin (NRG) family of ErbB3 ligands remains the 
most well established mechanism of ErbB3 activation [21-
23].
Neuregulins, like all EGF family ligands, are 
generated as transmembrane precursor proteins. 
Cleavage of the ectodomain is achieved by the ADAMs 
(A disintegrin and metalloproteinase) family of zinc-
dependent membrane-associated metalloproteinases 
[23, 24], which release the active ligand. ADAM-
mediated cleavage can be regulated by oncogenes and 
other intracellular signals such as protein kinase C [25-
27], but additional details of the molecular mechanisms 
determining neuregulin release are limited. Herein, we 
report a novel mechanism of NRG1 regulation involving 
Trop2. NRG1 interacts with Trop2, and when Trop2 is 
lost, an increase in surface expression of NRG1, NRG1 
cleavage, and ErbB3 activation occurs. The relationship 
between low Trop2 expression and elevated ErbB3 
activation was also observed in primary HNSCC tumors, 
and importantly, we demonstrate that Trop2 loss confers 
sensitivity to ErbB3 antibodies in tumor xenografts 
derived from HNSCC cells. 
RESULTS
To investigate the relationship between Trop2 loss 
and signaling in HNSCC, we examined the effects of 
reducing Trop2 levels in head and neck squamous cancer 
cells. Using two short-hairpins targeting unique regions 
of the Trop2 coding sequence, Trop2 levels were first 
reduced in the SCC-1 oral squamous cell cancer cell 
line (Figure 1A&C). As Trop2 resides in large part at the 
cell surface (in addition to the cytosol), we reasoned that 
Trop2 is likely to modify signals originating at the plasma 
membrane and chose to globally interrogate signaling 
changes caused by Trop2 loss using an unbiased phospho-
proteomic approach. Therefore, using an antibody array 
that simultaneously captures the signaling status of forty-
two transmembrane receptor tyrosine kinases, many of 
which are implicated in tumor biology, we measured the 
effects of Trop2 loss on phosphorylated (activated) forms 
of these proteins. Protein lysates from SCC-1 control and 
knockdown cells were generated and exposed to antibody 
arrays. Strikingly, the only receptor whose activation was 
observed to increase upon Trop2 loss was ErbB3 (Figure 
1B), a member of the ErbB family implicated in several 
aspects of aggressive tumor behavior [28-30]. No increase 
in signaling in any other ErbB family members or other 
pathways such as IGF-1R was detected after Trop2 loss. 
Interestingly, the p-Met signal is significantly attenuated 
after Trop2 loss, possibly due to a negative feedback 
mechanism (Supplementary Figure 1).
To confirm that Trop2 loss induces ErbB3 activation 
in HNSCC cells, we measured the levels of p-ErbB3 
levels after Trop2 depletion in SCC-1, SCC-25, and Cal 
27 cells by immunoblot analysis. Consistent with the 
result observed on the antibody array, when Trop2 protein 
expression was reduced, ErbB3 became activated as 
revealed by Tyr1289 phosphorylation using a phospho-Oncotarget 9283 www.impactjournals.com/oncotarget
specific antibody (Figure 1C &D, Supplementary Figure 
2A). In addition, downstream signaling to AKT was also 
increased upon Trop2 loss as judged by immunoblots 
against Ser473 phosphorylation on AKT. To rule out 
the possibility that the observed Trop2 loss-induced 
ErbB3 activation was caused by an off-target effect from 
RNA interference, we further investigated the specific 
contribution of Trop2 to ErbB3 activity. An RNAi-
resistant Trop2 cDNA was engineered by generating 
silent mutations in the cognate sequence targeted by the 
vector shTrop2.1. Upon lentiviral transduction of this 
plasmid into SCC1-shTrop2.1 cells, Trop2 re-expression 
was able to reduce ErbB3 and AKT activation (Figure 1E). 
In a parallel experiment, we transduced a Flag-epitope 
tagged Trop2 cDNA into parental SCC-1 cells and found 
it capable of suppressing basal levels of p-ErbB3 and 
subsequent AKT activity (Figure 1F). Collectively, these 
results suggest that Trop2 can function as an inhibitor of 
ErbB3 activity.
Next, we sought to determine whether an inverse 
Figure 1: Trop2 Loss Promotes ErbB3 Activation in HNSCC Cells. A. Immunofluorescence images of Trop2 staining (green) in 
SCC1 HNSCC cells after stable knockdown using short hairpins targeting the Trop2 cDNA. Nuclei are counterstained with 4’6-diamidino-
2-phenylindole (DAPI). B. Results of a phosphorylated receptor tyrosine kinase antibody array demonstrating elevated p-ErbB3 in lysates 
from Trop2 knockdown SCC1 cells. The exposures were normalized to the control spots (four corners), which exhibit equal intensities. 
C&D. Representative immunoblots showing hyperactivation of ErbB3 and AKT caused by Trop2 loss in SCC1 and SCC25 HNSCC cells. 
Two short hairpins targeting distinct regions of the Trop2 cDNA were used. E. Reduction of ErbB3 activity after ectopic expression of an 
RNAi-resistant Trop2 cDNA in Trop2 knockdown SCC1 cells. Arrow points to the lower band which is the correct size for Trop2. F. Ectopic 
expression of a Flag-epitope tagged Trop2 cDNA in SCC1 cells suppresses basal ErbB3 and AKT activation. Control is an empty vector. 
Relative increases in phosphoproteins in control versus experimental groups were quantified by photodensitometry after normalization to 
total ErbB3 or AKT protein which served as an internal controls. Immunoblots are representative of at least three independent experiments. 
Significance was measured by student’s t test, * (P<0.05), ** (P<0.01), *** (P<0.001). Oncotarget 9284 www.impactjournals.com/oncotarget
correlation between Trop2 and NRG1-ErbB3 pathway 
activation could be identified across tumors from HNSCC 
patients. Ideally, we would have liked to determine 
whether NRG1 is cleaved in the absence of Trop2 in 
tumor samples, but cleavage specific antibodies are not 
available and the multiple variant isoforms of NRG1 exist 
further making such an approach ambiguous. Therefore, 
to judge the relationship between activation of the 
NRG1-ErbB3 pathway and Trop2 expression, we chose 
to measure the presence of ErbB3 phosphorylation and 
correlate this with Trop2 status. We reasoned that tumors 
that are predominantly Trop2 positive would have minimal 
evidence of p-ErbB3 expression, and conversely, those 
with less Trop2 expression would exhibit more p-ErbB3 
staining. To address these issues, we obtained thirty-nine 
freshly cut sections of primary HNSCC and examined 
multiple regions of each section. P-ErbB3 expression was 
not observed in any of the thirty-one tumors that showed 
uniform Trop2 expression. We never observed a signal for 
p-ErbB3 in any Trop2 positive cells although total ErbB3 
expression was found to be comparable in Trop2 positive 
and negative tumors (Supplementary Figure 3). In contrast, 
tumors that were Trop2 negative were the only ones to 
show evidence of p-ErbB3 staining (P=0.0001, Figure 
2A-G, Supplementary Figure 3). Hence, in accord with 
the observation that Trop2 loss triggers ErbB3 activation 
in cell culture models of HNSCC, ErbB3 activation is 
inversely correlated with loss of Trop2 expression in 
primary HNSCC. 
To investigate the relationship between Trop2 and 
p-ErbB3 in a larger cohort of tumors, we analyzed TCGA 
dataset. Unfortunately, protein expression for Trop2 is 
Figure 2: Inverse Correlation Between Trop2 and p-ErbB3 in Primary HNSCC. Enumeration of ErbB3 positive or negative 
tumors as a function of Trop2 staining reveals an inverse correlation significant to P=0.0001 (Fisher’s exact test). Immunohistochemical 
staining of a representative squamous cell cancer showing membrane expression of p-ErbB3 (B) and absence of Trop2 expression in 
an adjacent section (C) in a tumor section showing poorly differentiated squamous histology after hematoxylin and eosin staining (D). 
Immunohistochemical staining of a representative squamous cell cancer showing absence of p-ErbB3 expression (E) and increased Trop2 
expression in an adjacent section (F) in a tumor showing well-differentiated histology after hematoxylin and eosin staining (G). Images are 
photographed at 20x power.Oncotarget 9285 www.impactjournals.com/oncotarget
not available, and therefore we correlated Trop2 mRNA 
expression with total and p-ErbB3 protein expression. 
We previously reported that Trop2 mRNA expression is 
reduced in the mesenchymal group of tumors [7], which 
represented  approximately  twenty-five  percent  of  the 
total number of tumors from the Chung dataset [2]. We 
confirmed  the  association  between  low  Trop2  mRNA 
expression and the mesenchymal subtype in TCGA (log-
fold change -1.1, P= 5x10-13), where the mesenchymal 
subtype represents twenty-four percent of tumors (Figure 
3). Next, we analyzed ErbB3 signaling as a function of 
HNSCC subtype using the TCGA reverse phase protein 
array (RPPA) data. In this analysis, we found that both 
total ErbB3 and p-ErbB3 (pY1298) were expressed at 
higher levels in the mesenchymal subtype compared to 
the other subtypes (log-fold change 0.6, P=7x10-4 for total 
ErbB3, and log-fold change 0.6, P=9x10-4, for p-ErbB3). 
These data confirm the relationship between low Trop2 
expression and enrichment for ErbB3 activity that we 
initially observed in our functional studies of Trop2 loss.
To elucidate the mechanism responsible for Trop2-
loss induced ErbB3 activation, we first examined whether 
basal p-ErbB3 levels in control SCC1 cells are sensitive 
to removal of growth factor. We observed that after two 
hours of serum starvation, levels of ErbB3 activity were 
reduced by over one-half in shLacZ control cells (Figure 
4A). We then examined whether the heightened ErbB3 
activity in Trop2 knockdown cells was also sensitive to 
growth factor deprivation, and observed a similar level 
of reduction of p-ErbB3 in these cells as was observed 
in shLacZ control cells. To further investigate the role of 
growth factors in Trop2-loss induced p-ErbB3 activation, 
we asked whether reducing Trop2 levels results in the 
secretion of an ErbB3-activating ligand that could replace 
the ability of growth factor-containing serum to stimulate 
ErbB3 activity in shLacZ control cells. To address this 
question, we reasoned that shLacZ-bearing control SCC-1 
cells, which exhibit a low level of basal ErbB3 activity, 
could serve as a system to assay for a putative soluble 
ligand. We generated conditioned media from Trop2 
knockdown and control cells by growing cells in serum-
free media for twenty-four hours and added this media to 
the different cell populations that had been serum starved 
for two hours. Importantly, only conditioned media from 
Trop2 knockdown cells was able to activate serum-starved 
shLacZ control cells, indicating release of an ErbB3-
stimulating ligand upon Trop2 loss (Figure 4A). Next we 
sought to determine the identity of the ligand responsible 
for this activity. As neuregulins are the only ligands 
known to activate ErbB3 and NRG1 has been reported 
to be expressed in a subset of HNSCC tumors [12], we 
considered that this family member would be a likely 
candidate for regulation by Trop2. We therefore measured 
the effects of reducing Trop2 levels on soluble and full-
Figure 3: Inverse Correlation Between Trop2 and p-ErbB3 as a Function of HNSCC Subtypes in the TCGA HNSCC 
Dataset . Box and whisker plots of Trop2 expression (left panel) and total and p-ErbB3 protein expression by RPPA (middle and right 
panels respectively), as functions of Chung and TCGA subtype calls. The data reveal increased total and p-ErbB3 activation in the 
mesenchymal (group 2, Trop2-low) subtype. Oncotarget 9286 www.impactjournals.com/oncotarget
length NRG1. Using an antibody that recognizes the 
amino terminus of NRG1, significantly increased NRG1 
ectodomain protein levels were identified in concentrated 
media taken from Trop2 knockdown SCC1 cells. Similar 
results were obtained in Trop2 knockdown SCC25 and 
Cal 27 cells (Figure 4B and Supplementary Figure 2B). 
Interestingly, we did not observe an increase in levels 
of full length cellular NRG1 upon Trop2 knockdown 
despite observing increased NRG1 in the media (Figure 
4B), suggesting that Trop2 is regulating NRG1 secretion 
rather than production or destruction. Conversely, 
overexpression of a Flag epitope-tagged Trop2 cDNA 
in SCC1 cells significantly reduced the basal levels of 
released NRG1 relative to levels in control SCC1 cells 
harboring an empty vector (Figure 4C). To determine 
whether NRG1 is required for the increased ErbB3 activity 
observed upon Trop2 loss, we simultaneously depleted 
Trop2 and NRG1 in HNSCC cells. We tested five NRG1 
short  hairpins,  but  only  one,  shNRG1.2,  significantly 
reduced NRG1 levels. Using this hairpin, we found that 
Figure 4: Trop2 Loss Activates ErbB3 Through NRG1. A. Serum-free conditioned media from Trop2 knockdown cells stimulates 
ErbB3 activity in SCC1 cells. Cells grown in serum-free media for two hours show decreased ErbB3 activity by immunoblot analysis (lanes 
1 vs. 2 and 5 vs. 6) that is increased after two hour exposure to conditioned media (C.M.) from Trop2 knockdown cells (shown in lanes 4 
and 8) but not by conditioned media from shLacZ control knockdown cells (shown in lanes 3 and 7). Media was conditioned for twenty-four 
hours prior to harvest. B. Immunoblot analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media 
or whole cell lysates (W.C.L.) taken from Trop2 knockdown or LacZ control cells. Blots show increased NRG1 secretion but no change 
in cellular full length NRG1 (FL NRG1) in the absence of Trop-2. Trop2 knockdown lanes are normalized to shLacZ. C. Immunoblot 
analysis of NRG1 protein levels from equal amounts of concentrated serum-free conditioned media taken from SCC1 cells harboring an 
empty vector or a Flag epitope-tagged Trop2 cDNA shows reduced soluble NRG1 upon Trop2 expression. Trop2 overexpression lane is 
normalized to vector control values. D. Immunoblot analysis showing that NRG1 knockdown in Trop2-depleted cells suppresses Trop2-
loss induced ErbB3 activation. FL NRG1 is full length NRG1. Significance was measured student’s t test, * (P<0.05), ** (P<0.01), *** 
(P<0.001).Oncotarget 9287 www.impactjournals.com/oncotarget
NRG1 depletion significantly reduced p-ErbB3 levels in 
Trop2 knockdown cells, indicating an essential role for 
NRG1 in this process (Figure 4D). Collectively, these data 
point to a role for Trop2 in modulating autocrine ErbB3 
activation by titrating the amount of NRG1 that is released 
from its precursor form.
We then considered possible ways by which 
Trop2 might modulate NRG1 release. Neuregulins 
localize to cytoplasmic and nuclear pools depending 
on cell type [31], and are brought to the cell surface 
and exist as transmembrane precursor proteins prior to 
cleavage and release of the ectodomain at the plasma 
membrane. Consistent with these reports, by indirect 
immunofluorescence  staining  we  found  NRG1  to  be 
primarily intracellular in SCC1 cells, visible in both 
cytosolic and nuclear compartments (Supplementary 
Figure 4). Given these observations, we investigated 
whether the absence of Trop2 increases the cell surface 
concentration of NRG1, which would provide a 
mechanism of increased NRG1 cleavage and release upon 
Trop2 loss. To test this possibility, we suppressed NRG1 
cleavagewith batimastat, an ADAM17 inhibitor, so as to 
be able to measure the contribution of Trop2 loss on static 
levels of NRG1 on the cell surface. After Trop2 depletion 
Figure 5: Functional and Physical Interaction Between Trop2 and NRG1. A. Membrane biotinylation and streptavidin 
immunoprecipitation (IP) reveals an accumulation of cell-surface NRG1 (full length) in Trop2 knockdown SCC1 cells once cleavage is 
suppressed by batimastat (twenty-four hour treatment). B. Immunblot analysis of biotinylated, streptavidin-precipitated membrane and 
flow-through cytosolic protein fractions isolated from SCC1 cells after Flag-epitope tagged Trop2 overexpression showing a dramatic 
increase in cytosolic concentrations of both Trop2 (anti-Flag antibody) and full-length NRG1. C. Immunoprecipitation of NRG1 followed 
by anti-Flag immunoblot of lysates isolated from cells harboring an empty vector or Flag epitope-tagged Trop2 cDNA reveals an interaction 
with Trop2 (left panel). The converse experiment (right panel) showing immunoprecipitation using anti-Flag antibodies followed by anti-
NRG1 immunblot also reveals the NRG1-Trop2 interaction. D. Immunoprecipitation of NRG1 (left panel) or endogenous Trop2 (right 
panel) followed by immunoblotting of protein lysates from shLacZ or shTrop2.1 cells using the converse antibodies confirms the NRG1-
Trop2 complex. Trop2 knockdown cells serve as a negative control. Results are representative of three independent experiments.Oncotarget 9288 www.impactjournals.com/oncotarget
in SCC1 cells, we isolated the plasma membrane fraction 
of cellular proteins by cell-surface biotinylation followed 
by streptavidin immunoprecipitation, and immunoblotted 
for NRG1. Strikingly, only in batimastat-treated Trop2 
knockdown cells did an increase in membrane-associated, 
full-length NRG1 become apparent (Figure 5A).
Next, we examined the effects of ectopic Trop2 
overexpression on NRG1 localization; Trop2 localizes to 
both the membrane and cytoplasm (Supplementary Figure 
5) and we asked whether increasing Trop2 concentrations 
in either of these locations would accordingly increase 
the resident amount of NRG1. We again performed cell-
surface biotinylation and streptavidin immunoprecipitation 
to examine membrane concentrations of Trop2 and NRG1, 
and also examined the effects of increased Trop2 on the 
cytoplasmic pools of NRG1 by cytosolic fractionation 
(Figure 5B). Ectopic Trop2 expression increased Trop2   
levels in both in membrane and cytosolic fractions, and 
NRG1 levels were also comparably elevated in these 
compartments relative to cells infected with an empty 
vectorŠ. Taking the effects of both gain- and loss-of 
function of Trop2 on NRG1 localization into account, 
these data suggest that Trop2 sequesters NRG1 and 
may influence its trafficking to or from the cell surface. 
Figure 6: Trop2 Loss Confers Dependency on ErbB3. A. Immunblot analysis of decreased p-ErbB3 in Trop2 knockdown HNSCC 
cells after four days of treatment with anti-ErbB3 antibodies (DL3.6b). B. Quantification of cell proliferation after seven days of anti-
ErbB3 treatment shows reduced proliferation only in Trop2 knockdown cells. Cell proliferation in LacZ controls was unaffected (not 
shown). Numbers were normalized to untreated cells. Columns mean, bars SE. (*,P<0.01 Fisher’s exact test). C. The anti-ErbB3 antibody 
has a specific effect against Trop2-low, ErbB3-activated SCC1 cells. N=5 mice/group. Mice received 25mg/kg antibody weekly for four 
weeks. P<0.0001, ANOVA.Oncotarget 9289 www.impactjournals.com/oncotarget
To develop insight into how this might occur, we 
sought evidence of a NRG1-Trop2 protein interaction. 
We immunoprecipitated endogenous soluble NRG1 in 
Trop2-Flag expressing cells, immunoblotted resolved 
proteins with anti-Flag antibodies, and observed evidence 
of NRG1-Trop2 complex formation (Figure 5C). 
Immunoprecipitation of protein lysates from these cells 
with the anti-Flag antibody further revealed evidence 
of a NRG1-Trop2 complex. In addition, when either 
NRG1 or endogenous Trop2 was immunoprecipitated 
from cells expressing the control hairpin, the existence 
of a NRG1-Trop2 complex was also observed, and 
immunoprecipitations from the knockdown cells served 
as negative controls (Figure 5D). Lastly, using the RNAi-
resistant Trop2 cDNA as a template, we constructed Trop2 
mutants harboring a deletion in either the EGF-like or 
thyroglobulin type-1 domains present in the extracellular 
region, both of which are required by Trop2 to bind IGF-
1 in lung cancer cells [10]. Similar to this requirement, 
deletion of either domain abolishes the Trop2 interaction 
with NRG1, and importantly, eliminates the ability of the 
mutants to suppress ErbB3 activity in Trop2 knockdown 
cells (Supplementary Figure 7). Collectively, these results 
indicate that Trop2 is part of a complex with NRG1, and 
suggest that Trop2 loss increases NRG1 accessibility to 
the membrane-bound cleavage machinery.
Tumors can become addicted to the oncogenic 
signaling stimulated by ErbB3 activation [12, 32], a 
situation reminiscent of the addiction to Ras and other 
oncogenes that occurs in other cancers. In particular, 
tumors in which NRG1 triggers ErbB3 signaling have been 
found to be sensitive to anti-ErbB3 antibody treatment 
[33]. Based on these observations, we considered that if 
NRG1 is in fact critical for Trop2-loss induced ErbB3 
activation, then interfering with the NRG1-ErbB3 axis 
should exert an inhibitory effect that is specific to Trop2 
knockdown cells. To test this possibility, we measured the 
effect of treatment with an anti-ErbB3 antibody (a gift 
Figure 7: Model of Trop2 Regulation of NRG1. A. NRG1 is predominantly a cytosolic protein and interacts with Trop2, which 
resides both in the cytosol and membrane pools. It is unknown whether Trop2 and NRG1 interact at the membrane and whether there 
are pools of the complex that transit to and/or from the membrane. The yellow ellipses represent endosomes. B. Trop2 loss results in a 
subsequent accumulation of NRG1 at the cell surface where it can be cleaved and released. Oncotarget 9290 www.impactjournals.com/oncotarget
from Genentech) on proliferation in vitro. Equal numbers 
of cells were seeded in tissue culture dishes, exposed to 
treatment with antibody for one week, harvested, and cell 
numbers assayed. Anti-ErbB3 antibodies can block ligand 
binding, receptor activation, and induce downregulation 
[33], and the latter two phenomena were readily detectable 
in Trop2 knockdown cells treated with the anti-ErbB3 
antibody within four days of treatment (Figure 6A). 
Importantly, the loss of ErbB3 activity in Trop2 depleted 
cells was associated with a decrease in cell number when 
enumerated after seven days of treatment (Figure 6B), 
results that suggested to us that anti-ErbB3 antibodies 
would also be useful to treat tumors in which Trop2 loss 
stimulates the NRG1-ErbB3 axis. To determine if this is 
the case, we performed a proof-of principle experiment 
by evaluating the effects of treatment with the anti-ErbB3 
antibody on tumor xenografts derived from control or 
Trop2 knockdown SCC-1 cells. Trop2 knockdown cells 
exhibit a small growth advantage over control cells when 
grown as tumor xenografts in immunocompromised mice, 
but this increase is not statistically significant (data not 
shown). However, when xenografts were allowed to grow 
to 400 mm3 in size prior to weekly antibody treatment, 
the  potent  and  specific  anti-tumor  properties  of  the 
ErbB3 antibodies against the tumors lacking Trop2 was 
revealed. These tumors ceased to grow within one week 
of treatment, and failed to grow for the duration of the 
four week experiment. In stark contrast, no anti-tumor 
effect was observed in control cells (Figure 6C). Together, 
the  in vitro and in  vivo data indicate that anti-ErbB3 
antibodies are likely to have potent anti-tumor properties 
against cancers that exhibit low Trop2 and high p-ErbB3 
expression.
DISCUSSION
For  numerous  tumor  types,  the  identification  of 
specific molecular features that define intrinsic subsets 
has dramatically improved the ability to predict the 
efficacy of many targeted therapies and has facilitated the 
rational development of novel therapeutics. The treatment 
of HER2Neu amplified breast cancer with trastuzumab 
and b-Raf mutant melanoma with vemurafenib are two 
examples where subtyping has had a transformative 
impact [34]. The power of subtyping, whether it is 
based on genomic or epigenetic signatures, lies in the 
identification of the underlying biology that drives the 
subset of cancers, allowing for tailored and targeted 
treatments. Unfortunately, subtyping in HNSCC has yet 
to be integrated into the treatment of this disease. The use 
of cetuximab in HNSCC exemplifies these deficits: its 
efficacy is limited to a minority of patients and no tumor 
characteristics have been identified and adopted to select 
for these patients [35]. Our published analysis of the Chung 
dataset [7], the currently presented analyses of TCGA 
dataset, and the results from our immunohistochemical 
study of primary tumors from our institution, combined 
with the functional data shown herein point to strong 
correlations between the mesenchymal subtype, low Trop2 
expression, and elevated ErbB3 activity.
Recent studies show that both gain- and loss-
of-function of Trop2 can activate oncogenic signaling 
depending on context [7, 10, 36, 37], however, the ability 
of Trop2 to influence NRG1 trafficking and release is an 
unexpected finding. Although modulation of the level of 
NRG1 cleavage by titration of ADAM17 activity is well 
established (reviewed in [23, 38]), little is known about 
how the growth factor itself is regulated independent of 
ADAM17 activity. Interest in understanding how NRG1 
is regulated is growing now that the role of ErbB3 as a 
mediator of treatment resistance and aggressiveness is 
becoming widely recognized [19, 39]. One report argues 
for modulation of NRG1 expression at the level of 
transcription in some HNSCC tumors [12]. More recently, 
another layer of regulation, namely phosphorylation 
of NRG1 by protein kinase C (PKC) prior to cleavage, 
has been documented [27]. The ability of Trop2 to 
influence  NRG1  trafficking  and  cleavage  now  adds 
another layer of regulation. We note that how Trop2 loss 
results in increased cell-surface NRG1 is unclear. One 
possibility, our favored model, is that Trop2 functions 
as an intracellular retention factor for a distinct pool of 
NRG1 that is otherwise destined to transit to the cell 
surface (Figure 7A&B). Alternatively, Trop2 could recycle 
ambient cell-surface NRG1 such that only in the absence 
of Trop2 is NRG1 retained at the membrane long enough 
to be cleaved and released. 
The observations reported herein that tumors lacking 
Trop2 exhibit heightened ErbB3 activity have important 
clinical implications. The use of ErbB3 pathway inhibitors 
as anti-cancer therapeutics is an area of active clinical 
investigation, but the range of susceptible target tumors 
is unknown. Previous work has demonstrated that ligand-
dependent ErbB3 activation renders tumors susceptible to 
anti-ErbB3 antibodies [33], and our observation that the 
anti-ErbB3 antibody can suppress both proliferation and 
tumorigenic growth of ErbB3 activated cells is consistent 
with these findings. While the relationship between NRG1 
expression and outcome in primary HNSCC has not been 
reported to our knowledge, elevated expression of ErbB3, 
a possible surrogate for activity, has been associated 
with a poor prognosis in a variety of cancer types [28-
30]. Based on an analysis of NRG1 and ErbB3 mRNA 
in recurrent HNSCC, post-treatment, late stage disease 
also appears to be enriched for NRG1-mediated ErbB3 
activation [40]; whether Trop2 loss is a mechanism for 
autocrine activation of ErbB3 in this context remains to be 
evaluated. Should this be the case, Trop2 could prove to 
be a useful biomarker for ErbB3 activation and therapeutic 
stratification  in  the  setting  of  recurrent  HNSCC,  an 
incurable disease for which treatment options are limited. 
We also note that not all Trop2 negative tumors were found Oncotarget 9291 www.impactjournals.com/oncotarget
to be positive for p-ErbB3 expression. This observation is 
could be due to a subgroup of Trop2 negative HNSCC 
for which ErbB3 signaling is dispensible; also possible 
is that clinical tumor procurement procedures are not yet 
optimized for capturing the presence of phospho-proteins 
which are known to be highly labile.
The mechanisms governing Trop2 expression 
are also not well understood. We note that Trop2 
overexpression has been reported in some tumors, 
including HNSCC [37, 41]; however, we and others 
have reported high-level basal expression of Trop2 in 
normal epithelia of the tonsil and oral cavity, as well as 
other stratified squamous epithelia [7, 42]. Therefore, the 
significance of these other findings remains unclear. The 
recent identification that Trop2 is subjected to regulated 
intramembrane proteolysis in prostate cells suggests that 
in some contexts, Trop2 regulation may be a dynamic 
process [36]. In contrast, Trop2 has been reported to be 
inactivated by methylation in some lung cancers [10], 
motivating us to begin to investigate the methylation status 
of the Trop2 promoter in tumors from TCGA dataset. 
Ongoing studies such as these are designed to further 
characterize the molecular details and dependencies 
arising in the mesenchymal subset of HNSCC.
To  conclude,  we  have  identified  a  direct  link 
between Trop2 and NRG1-ErbB3 signaling in a subset 
of HNSCC. These data provide a foundation for further 
functional studies of NRG1 trafficking as well as Trop2 
biology. In addition, more extensive genomic and 
proteomic analyses of Trop2-low HNSCC will likely 
uncover additional information that will be useful to 
unravel the molecular basis of aggressive epithelial 
tumorigenesis. Most importantly, the work described 
herein delineates a framework for near-term clinical 
studies of ErbB3 inhibitors against a group of tumors for 
which these inhibitors are likely to have a high chance of 
success.
MATERIALS AND METHODS
Cell culture 
UM-SCC1 (provided by University of Michigan), 
SCC25, and Cal 27 (both from ATCC) were grown 
in  DMEM/F12  containing  10%  FBS.  Cell  lines  were 
authenticated and matched in February 2013 to short 
tandem repeat DNA using the Johns Hopkins University 
Fragment Analysis Facility. 
RNA Interference
Stable short hairpins targeting human Trop-2 
cDNA with the following sequences were cloned into the 
lentiviral vector pLKO-puro (provided by S.A.Stewart, 
Washington University): GCGCACGCTCATC 
TATTACCT (nucleotides 1377-1397, ShTrop2.1). 
CGTGGACAACGATGGCCTCTA (nucleotides 906-926, 
ShTrop2.2). A short hairpin targeting lacZ was used as a 
negative control (provided by S.A. Stewart, Washington 
University in St. Louis). RNAi (1377) resistant hTrop2 
sequence is 5’-gcgcacgctgatatactacct, which contains 
four nucleotides with silent point mutation in RNAi 
target region using Stratagene Quick Change II Site 
Mutagenesis Kit. The NRG1 short hairpin sequence is 
GCCTCAACTGAAGGAGCATAT. Lentivirus infection 
was performed as described previously [8]. After infection, 
cells were selected in puromycin.
Phospho-receptor tyrosine kinase array
The phospho-RTK array (R&D Systems) 
specifically screens for membrane associated receptors. 
Antibodies against 42 different RTKs were pre-spotted in 
duplicate on nitrocellulose membranes. Cell lysates from 
SCC1 ShLacZ and ShTrop2 cells were incubated with the 
membrane according to the manufacturer’s instructions. 
Thereafter, a pan anti-phosphotyrosine antibody was used 
to detect the phosphorylated tyrosine on activated RTKs. 
The blots were also developed using the ECL method.
Immunoblotting and Immunoprecipitation
Cells were lysed and homogenized with RIPA 
lysis buffer with protease inhibitors. Antibodies used 
in western blotting include: rabbit anti-phospho-AKT 
(#4060, Ser473, Cell Signaling), rabbit anti-phospho-
HER3 (#4791, Tyr1289, Cell Signaling) and mouse or 
rabbit anti-ErbB3 (Santa Cruz Biotechnology), rabbit 
anti-NRG1 (Santa Cruz Biotechnology), mouse anti-
NRG1 (MAB377, R&D Systems), goat anti-human Trop2 
(AF650, R&D Systems), anti-ZO-1 (Life Technologies). 
The immunoblots were developed using the ECL method 
(Thermo Scientific). 
For immunoprecipitation, cells were scraped off the 
plates and washed with PBS. Lysis buffer (25mM Tris-Cl, 
PH 7.5, 225mM NaCl, 5% Glycerol, 1mM EDTA, 25mM 
NaF, 0.5% NP-40) with protease inhibitor cocktail (Sigma-
Aldrich) was used to resuspend the cells. Cell lysates were 
rocked at 4 ºC for 20 minutes. The insoluble fraction was 
removed by centrifugation at 12,000g for 5 minutes. 500 
μg of total protein was used and anti-NRG1 antibody 
(MAB377, R&D Systems) or anti-Trop2 antibody (AF650, 
R&D Systems) was added to the cell lysate for overnight 
incubation at 4 ºC, then protein G beads were added, 
and rocked 2-4 hours. 15 μg of protein from the whole 
cell lysate was resolved and blotted as a loading control. 
The beads were washed with lysis buffer four times and 
proteins resolved by SDS-PAGE. Biotinylation was 
performed according to the manufacturer’s instructions Oncotarget 9292 www.impactjournals.com/oncotarget
(Pierce, Thermo Scientific).
Immunofluorescence, Immunohistochemistry, and 
Tissue Samples and Processing
Cells were grown on glass coverslip and washed 
with PBS, fixed with 4% paraformadelhyde in PBS and 
permeabilized  with  0.1%  Triton  x-100  in  PBS. After 
several PBS washes, cells were stained for NRG1 (C-20, 
Santa Cruz Biotechnology) overnight at 4 ºC. Appropriate 
secondary antibodies were added for one hour at 37 ºC. 
Cells were mounted and viewed using a Zeiss Axio Plan 
2 Fluorescence Microscope. All human samples were 
collected in accordance with protocols approved by the 
institutional review board of Washington University 
Schools of Medicine and data handled confidentially as 
proscribed. 
In Vivo Tumor Xenograft Studies 
Athymic nude mice (4 to 6-week-old females) were 
obtained from Harlan Laboratories (Indianapolis, IN). A 
suspension of 2X106 SCC1 cells (ShLacZ or ShTrop2) 
was injected subcutaneously into the right flank of mice. 
Tumors were measured in length and width once a week 
and volumes were calculated using the formula (length x 
width2Xπ)/6. All implanted tumors were grown for five to 
six weeks until average tumor volume reached 400-500 
mm3 before treatment. At least five mice per group were 
treated with intraperitoneal injections of 25 mg/kg anti-
ErbB3 antibody (Genentech) weekly for five weeks and 
saline was used a negative control. The change of tumor 
volumes over time in different groups were described 
using slopes (i.e., the daily percent increase) and compared 
by a linear mixed model. The analysis was performed 
using SAS 9.3 (SAS Institutes, Cary, NC), with a 2-sided 
p-value of 0.05 to indicate statistical significance. 
TCGA Analysis
Both gene and protein expression were obtained 
from TCGA using R package cgdsr [43]. Gene expression 
was measured with RNA-sequencing and all analyses were 
performed on log transformed, RSEM V2 normalized 
gene level summaries. Reverse Phase Protein Arrays 
(RPPA) measured total and phospho protein expression, 
normalized as z-scores. Intrinsic subtypes were computed 
from RNA-sequencing using the classifier from [3] as 
part of the TCGA HNSCC analysis [44]. Differential 
expression analyses were computed using t-tests 
comparing expression in the mesenchymal subtype (MS; 
Chung Subtype 2) to expression in all other subtypes, 
i.e., Basal (BA; Chung Subtype 1), Atypical (AT; Chung 
Subtype 3), and Classical (CL; Chung Subtype 4). All 
analyses were performed on the subset samples reserved 
for publication for which RPPA measurements were also 
available as of March 26, 2014.
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